We are a life science innovation center that supports health tech entrepreneurs providing strategic mentorship and resources, experts and office space for growth.

THE MISSION

To accompany health tech startups to their next significant valuation milestones.

 

view more

OFFERS

Neighborhood offers tailed in-residence mentoring, coaching and global access to health tech entrepreneurs.

 

view more

Last events

meetings

Roundup of J.P. Morgan’s Annual Healthcare Conference

Tuesday January 15, 2019 - 18 h 00 min-21 h 30 min
View more
meetings

Healthtech : Digital IP and Open Source

Thursday November 8, 2018 - 18 h 00 min-20 h 00 min
View more
meetings

How to obtain a market approval for a health tech application or a software?

Thursday October 4, 2018 - 18 h 00 min-21 h 00 min
Agenda 18 h – 18 h 30: Welcome 18 h 30 – 19 h: Presentation from David Sainati, Founder ...
View more

COMMUNITY

HOW TO APPLY

Tell us about your idea, technology, or innovation and how we can work together to empower you to reach your next milestone in product development.

 

Join usI have a question

Would like to learn more
on our programs or take a tour?

op2 lysis

THERAPEUTIC AREA
Cardiology, neurology, stroke
LOCATION COUNTRY
Paris, France

WEBSITE
https://www.op2lysis.com

OP2lysis

Op2Lysis develops the first treatment for hemorrhagic stroke a life-threatening disease that affects >1,5M people every year worldwide. Op2lysis program aims at validating the clinical safety and the efficacy of its therapeutic solution to be ready to enter advanced phases of development by 2022. Op2Lysis is a biotech company dedicated to the development of innovative products to improve the benefit of lytic treatment in stroke, the first cause of acquired handicap worldwide. Christophe GAUDIN and Jérôme PARCQ are the co-founders of Op2Lysis, which benefits from their complementary experiences and skills.

op2 lysis

THERAPEUTIC AREA
Cardiology, neurology, stroke
LOCATION COUNTRY
Paris, France

WEBSITE
https://www.op2lysis.com

OP2lysis

Op2Lysis develops the first treatment for hemorrhagic stroke a life-threatening disease that affects >1,5M people every year worldwide. Op2lysis program aims at validating the clinical safety and the efficacy of its therapeutic solution to be ready to enter advanced phases of development by 2022. Op2Lysis is a biotech company dedicated to the development of innovative products to improve the benefit of lytic treatment in stroke, the first cause of acquired handicap worldwide. Christophe GAUDIN and Jérôme PARCQ are the co-founders of Op2Lysis, which benefits from their complementary experiences and skills.

op2 lysis

THERAPEUTIC AREA
Cardiology, neurology, stroke
LOCATION COUNTRY
Paris, France

WEBSITE
https://www.op2lysis.com

OP2lysis

Op2Lysis develops the first treatment for hemorrhagic stroke a life-threatening disease that affects >1,5M people every year worldwide. Op2lysis program aims at validating the clinical safety and the efficacy of its therapeutic solution to be ready to enter advanced phases of development by 2022. Op2Lysis is a biotech company dedicated to the development of innovative products to improve the benefit of lytic treatment in stroke, the first cause of acquired handicap worldwide. Christophe GAUDIN and Jérôme PARCQ are the co-founders of Op2Lysis, which benefits from their complementary experiences and skills.

op2 innovative drug

 

THERAPEUTIC AREA
Pharmacodynamic Modeling and Artificial Intelligence

LOCATION COUNTRY
Paris, France

 

 

 

 

 

 

Hillo

Hillo develops the first AI-based decision support platform for diabetic patients, based on a blood glucose levels predictive system that adapts to every patient’s physiology and habits. Our technology combines pharmacodynamic modeling and artificial intelligence, we develop tools for patients to help them anticipate and avoid hypo- or hyperglycemia, and for care teams to help them understand each patient’s specific glycemic response. We’ve demonstrated outstanding results and accuracy of our predictive technology through trials in hospitals.

 

 

man ros therapeutics

 

 

THERAPEUTIC AREA
Neuropathies 
LOCATION COUNTRY
Paris, France

 

 

 

Neurophoenix

Neurophoenix is a biotechnology company developing a revolutionary treatment for chronic and acute optic neuropathies such as glaucoma or retina ischemia. This novel approach is based on a molecule derived from a virus that has the remarkable property of reactivating the survival mechanism of injured neurons. Our molecule is the result of many years of academic research carried out by Monique Lafon, director of the Viral Neuro-immunology laboratory at Institut Pasteur. This research identified a molecule produced by the rabies virus with the remarkable capacity to both keep neurons alive (neuroprotection) and also stimulate axon regrowth from damaged neurons (neuroregeneration).

 

My vision

 

THERAPEUTIC AREA
Neuropathies
LOCATION COUNTRY
Paris, France

 

 

 

Aivision

Neurophoenix is a biotechnology company developing a revolutionary treatment for chronic and acute optic neuropathies such as glaucoma or retina ischemia. This novel approach is based on a molecule derived from a virus that has the remarkable property of reactivating the survival mechanism of injured neurons. Our molecule is the result of many years of academic research carried out by Monique Lafon, director of the Viral Neuro-immunology laboratory at Institut Pasteur. This research identified a molecule produced by the rabies virus with the remarkable capacity to both keep neurons alive (neuroprotection) and also stimulate axon regrowth from damaged neurons (neuroregeneration).